(78 days)
P920030, P020030/S1
No
The description details a standard immunoassay technology based on chemiluminescence and antibody binding, with no mention of AI or ML algorithms for data analysis or interpretation.
No.
The device is an immunoassay for the quantitative determination of prostate specific antigen (PSA) in serum, which is used to monitor cancer patients. It is a diagnostic tool, not a therapeutic one.
Yes
Explanation: The device is used for the quantitative determination of prostate specific antigen in serum "to aid in the management of cancer patients," indicating its use in diagnosing and monitoring a medical condition.
No
The device description clearly outlines a two-site immunoassay using physical reagents (antibodies, paramagnetic particles) and a chemiluminometric technology system (ACS:Centaur Automated Chemiluminescence Systems) to measure PSA. This involves hardware and chemical components, not just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of prostate specific antigen in serum." Serum is a biological sample taken from the body.
- Device Description: The description details a "two-site immunoassay using direct chemiluminometric technology," which is a common method for analyzing biological samples in a laboratory setting.
- Mechanism: The device measures the amount of PSA in a patient sample (serum) to aid in the management of cancer patients. This is a diagnostic process performed outside of the body.
The core function of the device is to analyze a biological sample (serum) in vitro (outside the body) to provide information for diagnosis or management of a disease (prostate cancer). This aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Chiron Diagnostics ACS:Centaur PSA2 Immunoassay is for the quantitative determination of prostate specific antigen in serum to aid in the management of cancer patients in whom changing concentrations of PSA are observed using the Chiron Diagnostics ACS:Centaur Automated Chemiluminescence Systems.
Product codes
LTJ
Device Description
Prostate-specific antigen (PSA) is a single-chain glycoprotein normally found in the cytoplasm of the epithelial cells lining the acini and ducts of the prostate gland. PSA is a neutral serine protease of 240 amino acids involved in the lysis of seminal coagulum.
PSA is detected in the serum of males with normal, benign hypertrophic, and malignant prostate tissue. PSA is not detected in the serum of males without prostate tissue (because of radical prostatectomy or cystoprostatectomy) or in the serum of most females. The fact that PSA is unique to prostate tissue makes it a suitable marker for monitoring men with cancer of the prostate. PSA is also useful for determining possible recurrence after therapy when used in conjunction with other diagnostic indices.
Measurement of serum PSA levels is not recommended as a screening procedure for the diagnosis of cancer because elevated PSA levels also are observed in patients with benign prostatic hypertrophy. However, studies suggest that the measurement of PSA in conjunction with digital rectal examination (DRE) and ultrasound provide a better method of detecting prostate cancer than DRE alone.
PSA levels increase in men with cancer of the prostate, and after radical prostatectomy PSA levels routinely fall to the undetectable range. If prostatic tissue remains after surgery or metastasis has occurred, PSA appears to be useful in detecting residual and early recurrence of tumor. Therefore, serial PSA levels can help determine the success of prostatectomy, and the need for further treatment, such as radiation, endocrine or chemotherapy, and in the monitoring of the effectiveness of therapy.
The Chiron Diaqnostics ACS:Centaur PSA2 immunoassay is a two-site immunoassay using direct chemiluminometric technology, which uses constant amounts of two antibodies. The first antibody, in the Lite Reagent, is a purified polyclonal sheep anti-PSA antibody labeled with acridinium ester. The second antibody, in the Solid Phase, is a monoclonal mouse anti-PSA antibody covalently coupled to paramagnetic particles. A direct relationship exists between the amount of PSA present in the patient sample and the amount of relative light units (RLU's) detected by the system.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
prostate gland
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The ACS:Centaur Immunoassay measures PSA concentration up to 135 ng/mL with a minimum detectable concentration of 0.06 ng/mL.
For 287 samples in the range of .07 to 111.25 ng/mL, the correlation between the ACS:Centaur PSA2 and the ACS:180 PSA2 is described by the equation: ACS:Centaur PSA2 = 0.97 (ACS:180 PSA2) + 0.19 ng/mL. Correlation coefficient (r) = 0.99.
Key Metrics
Sensitivity: "minimum detectable concentration of 0.06 ng/mL."
Accuracy: Correlation coefficient (r) = 0.99 (between ACS:Centaur PSA2 and ACS:180 PSA2)
Predicate Device(s)
P920030 & P020030/S1
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.6010 Tumor-associated antigen immunological test system.
(a)
Identification. A tumor-associated antigen immunological test system is a device that consists of reagents used to qualitatively or quantitatively measure, by immunochemical techniques, tumor-associated antigens in serum, plasma, urine, or other body fluids. This device is intended as an aid in monitoring patients for disease progress or response to therapy or for the detection of recurrent or residual disease.(b)
Classification. Class II (special controls). Tumor markers must comply with the following special controls: (1) A guidance document entitled “Guidance Document for the Submission of Tumor Associated Antigen Premarket Notifications (510(k)s) to FDA,” and (2) voluntary assay performance standards issued by the National Committee on Clinical Laboratory Standards.
0
AUG / 2 1998
Company Confidential Summary of Safety and Effectiveness
As required by 21 CFR 807.92, the following 510(k) Summary is provided:
1. Submitter Information
William J. Pignato Contact person:
Address:
Chiron Diagnostics Corporation 63 North Street Medfield, MA 02052
Phone: (508) 359-3825 (508) 359-3885 FAX: e-mail: william.pignato@chirondiag.com
Date Summary Prepared:
May 18, 1998
2. Device Information
ACS:Centaur PSA2 Immunoassay Proprietary Name: PSA Immunoassay Common Name: Reclassified to Class II, classification number Classification Name: unknown
3. Predicate Device Information
| Name: | ACS:180 PSA2 Immunoassay |
|---|---|
| Manufacturer: | Chiron Diagnostics |
| 510(k) Number: | P920030 & P020030/S1 (note reclassified to class II) |
4. Device Description
Prostate-specific antigen (PSA) is a single-chain glycoprotein normally found in the cytoplasm of the epithelial cells lining the acini and ducts of the prostate gland. PSA is a neutral serine protease of 240 amino acids involved in the lysis of seminal coagulum.
PSA is detected in the serum of males with normal, benign hypertrophic, and malignant prostate tissue. PSA is not detected in the serum of males without prostate tissue (because of radical prostatectomy or cystoprostatectomy) or in the serum of most females. The fact that PSA is unique to prostate tissue makes it a suitable marker for monitoring men with cancer of the prostate. PSA is also useful for determining possible recurrence after therapy when used in conjunction with other diagnostic indices.
1
Company Confidential
Measurement of serum PSA levels is not recommended as a screening procedure for the diagnosis of cancer because elevated PSA levels also are observed in patients with benign prostatic hypertrophy. However, studies suggest that the measurement of PSA in conjunction with digital rectal examination (DRE) and ultrasound provide a better method of detecting prostate cancer than DRE alone.
PSA levels increase in men with cancer of the prostate, and after radical prostatectomy PSA levels routinely fall to the undetectable range. If prostatic tissue remains after surgery or metastasis has occurred, PSA appears to be useful in detecting residual and early recurrence of tumor. Therefore, serial PSA levels can help determine the success of prostatectomy, and the need for further treatment, such as radiation, endocrine or chemotherapy, and in the monitoring of the effectiveness of therapy.
5. Statement of Intended Use
The Chiron Diagnostics ACS:Centaur PSA2 Immunoassay is for the quantitative determination of prostate specific antigen in serum to aid in the management of cancer patients in whom changing concentrations of PSA are observed using the Chiron Diagnostics ACS:Centaur Automated Chemiluminescence Systems.
Summary of Technological Characteristics 6.
The Chiron Diaqnostics ACS:Centaur PSA2 immunoassay is a two-site immunoassay using direct chemiluminometric technology, which uses constant amounts of two antibodies. The first antibody, in the Lite Reagent, is a purified polyclonal sheep anti-PSA antibody labeled with acridinium ester. The second antibody, in the Solid Phase, is a monoclonal mouse anti-PSA antibody covalently coupled to paramagnetic particles. A direct relationship exists between the amount of PSA present in the patient sample and the amount of relative light units (RLU's) detected by the system.
7. Performance Data
Sensitivity
The ACS:Centaur Immunoassay measures PSA concentration up to 135 ng/mL with a minimum detectable concentration of 0.06 ng/mL.
Accuracy
For 287 samples in the range of .07 to 111.25 ng/mL, the correlation between the ACS:Centaur PSA2 and the ACS:180 PSA2 is described by the equation:
ACS:Centaur PSA2 = 0.97 (ACS:180 PSA2) + 0.19 ng/mL
Correlation coefficient (r) = 0.99
ACS:Centaur PSA2 510(k)
22 May, 1998
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized symbol that resembles three human profiles facing right, with flowing lines beneath them.
AUG | 2 |998
Mr. Thomas F. Flynn Manager, Requlatory Affairs & Compliance Chiron Diagnostics Corporation 63 North Street Medfield, Massachusetts 02052
Re: к981839/51 ACS:Centaur PSA2 Immunoassay Trade Name: Regulatory Class: II Product Code: LTJ Dated: August 3, 1998 Received: August 4, 1998
Dear Mr. Flynn:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Druq Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
3
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Company Confidential
Page _ of _
510(k) Number (if known): K981839
Device Name: Chiron Diagnostics ACS:Centaur PSA2 Immunoassay
Indications for Use:
The Chiron Diagnostics ACS:Centaur PSA2 Immunoassay is for the quantitative determination of prostate specific antigen in serum to aid in the management of cancer patients in whom changing concentrations of PSA are observed using the Chiron Diagnostics ACS:Centaur Automated Chemiluminescence Systems.
Peter E. Maurer
(Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE--CONTINUE ON ANOTHER PAGE, IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use (Optional Format 1-2-96)
ACS:Centaur PSA2 510(k)